Napp Adriane E, Haase Robert, Laule Michael, Schuetz Georg M, Rief Matthias, Dreger Henryk, Feuchtner Gudrun, Friedrich Guy, Špaček Miloslav, Suchánek Vojtěch, Fuglsang Kofoed Klaus, Engstroem Thomas, Schroeder Stephen, Drosch Tanja, Gutberlet Matthias, Woinke Michael, Maurovich-Horvat Pál, Merkely Béla, Donnelly Patrick, Ball Peter, Dodd Jonathan D, Quinn Martin, Saba Luca, Porcu Maurizio, Francone Marco, Mancone Massimo, Erglis Andrejs, Zvaigzne Ligita, Jankauskas Antanas, Sakalyte Gintare, Harań Tomasz, Ilnicka-Suckiel Malgorzata, Bettencourt Nuno, Gama-Ribeiro Vasco, Condrea Sebastian, Benedek Imre, Čemerlić Adjić Nada, Adjić Oto, Rodriguez-Palomares José, Garcia Del Blanco Bruno, Roditi Giles, Berry Colin, Davis Gershan, Thwaite Erica, Knuuti Juhani, Pietilä Mikko, Kępka Cezary, Kruk Mariusz, Vidakovic Radosav, Neskovic Aleksandar N, Díez Ignacio, Lecumberri Iñigo, Geleijns Jacob, Kubiak Christine, Strenge-Hesse Anke, Do The-Hoang, Frömel Felix, Gutiérrez-Ibarluzea Iñaki, Benguria-Arrate Gaizka, Keiding Hans, Katzer Christoph, Müller-Nordhorn Jacqueline, Rieckmann Nina, Walther Mario, Schlattmann Peter, Dewey Marc
Department of Radiology, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany.
Department of Cardiology, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany.
Eur Radiol. 2017 Jul;27(7):2957-2968. doi: 10.1007/s00330-016-4620-z. Epub 2016 Nov 18.
More than 3.5 million invasive coronary angiographies (ICA) are performed in Europe annually. Approximately 2 million of these invasive procedures might be reduced by noninvasive tests because no coronary intervention is performed. Computed tomography (CT) is the most accurate noninvasive test for detection and exclusion of coronary artery disease (CAD). To investigate the comparative effectiveness of CT and ICA, we designed the European pragmatic multicentre DISCHARGE trial funded by the 7th Framework Programme of the European Union (EC-GA 603266).
In this trial, patients with a low-to-intermediate pretest probability (10-60 %) of suspected CAD and a clinical indication for ICA because of stable chest pain will be randomised in a 1-to-1 ratio to CT or ICA. CT and ICA findings guide subsequent management decisions by the local heart teams according to current evidence and European guidelines.
Major adverse cardiovascular events (MACE) defined as cardiovascular death, myocardial infarction and stroke as a composite endpoint will be the primary outcome measure. Secondary and other outcomes include cost-effectiveness, radiation exposure, health-related quality of life (HRQoL), socioeconomic status, lifestyle, adverse events related to CT/ICA, and gender differences.
The DISCHARGE trial will assess the comparative effectiveness of CT and ICA.
• Coronary artery disease (CAD) is a major cause of morbidity and mortality. • Invasive coronary angiography (ICA) is the reference standard for detection of CAD. • Noninvasive computed tomography angiography excludes CAD with high sensitivity. • CT may effectively reduce the approximately 2 million negative ICAs in Europe. • DISCHARGE addresses this hypothesis in patients with low-to-intermediate pretest probability for CAD.
欧洲每年进行超过350万例有创冠状动脉造影(ICA)检查。由于无需进行冠状动脉介入治疗,这些有创检查中约200万例可通过无创检查减少。计算机断层扫描(CT)是检测和排除冠状动脉疾病(CAD)最准确的无创检查。为了研究CT和ICA的相对有效性,我们设计了由欧盟第七框架计划资助的欧洲实用多中心DISCHARGE试验(EC-GA 603266)。
在本试验中,疑似CAD的预测试概率为低至中等(10%-60%)且因稳定型胸痛有ICA临床指征的患者将按1:1比例随机分为CT组或ICA组。CT和ICA检查结果将指导当地心脏团队根据现有证据和欧洲指南做出后续管理决策。
主要不良心血管事件(MACE)定义为心血管死亡、心肌梗死和中风的复合终点,将作为主要结局指标。次要结局和其他结局包括成本效益、辐射暴露、健康相关生活质量(HRQoL)、社会经济状况、生活方式、与CT/ICA相关的不良事件以及性别差异。
DISCHARGE试验将评估CT和ICA的相对有效性。
• 冠状动脉疾病(CAD)是发病和死亡的主要原因。• 有创冠状动脉造影(ICA)是检测CAD的参考标准。• 无创计算机断层扫描血管造影可高灵敏度地排除CAD。• CT可有效减少欧洲约200万例阴性ICA检查。• DISCHARGE试验针对CAD预测试概率为低至中等的患者验证这一假设。